We are live on ! Find out more
VERV

Verve Therapeutics
VERV

Delisted

VERV was delisted on the 24th of July, 2025.

Back to rankings

101 hedge funds and large institutions have $696M invested in Verve Therapeutics in 2022 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 32 increasing their positions, 21 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,827% more call options, than puts

Call options by funds: $3.87M | Put options by funds: $201K

59% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 17

52% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 21

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

10% more funds holding

Funds holding: 92 → 101 (+9)

2.37% less ownership

Funds ownership: 96.02% → 93.65% (-2.4%)

35% less capital invested

Capital invested by funds: $1.06B → $696M (-$368M)

Holders
101
Holders Change
+9
Holders Change %
+9.78%
% of All Funds
1.7%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.07%
New
27
Increased
32
Reduced
21
Closed
17
Calls
$3.87M
Puts
$201K
Net Calls
+$3.67M
Net Calls Change
+$4.71M

Top Buyers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
+$7.36M
2
BlackRock
BlackRock
New York
+$6.59M
3
Federated Hermes
Federated Hermes
Pennsylvania
+$6M
4
Millennium Management
Millennium Management
New York
+$5.76M
5
AIM
ARK Investment Management
Florida
+$5.38M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$31.9M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$16.8M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$15.7M
4
RCM
RA Capital Management
Massachusetts
-$7.08M
5
Rafferty Asset Management
Rafferty Asset Management
New York
-$4.22M
Name Holding Trade Value Shares
Change 		Change in
Stake
MCM
26
M28 Capital Management
Connecticut
$2.73M – – –
WP
27
Woodline Partners
California
$2.29M – – –
N
28
Nuveen
North Carolina
$2.28M +$261K +16,879 +13%
Charles Schwab
29
Charles Schwab
California
$2.21M -$134K -8,660 -6%
CSS
30
Cubist Systematic Strategies
Connecticut
$1.93M +$1.57M +101,663 +416%
Mirae Asset Global Investments
31
Mirae Asset Global Investments
South Korea
$1.8M +$1.82M +117,698 New
Sumitomo Mitsui Trust Group
32
Sumitomo Mitsui Trust Group
Japan
$1.76M +$1.78M +115,232 New
ECM
33
ExodusPoint Capital Management
New York
$1.74M +$1.77M +114,117 New
Bank of New York Mellon
34
Bank of New York Mellon
New York
$1.58M -$189K -12,231 -11%
EC
35
EcoR1 Capital
California
$1.51M – – –
NAMA
36
Nikko Asset Management Americas
New York
$1.49M +$761K +49,123 +74%
D.E. Shaw & Co
37
D.E. Shaw & Co
New York
$1.44M +$48.3K +3,119 +3%
Goldman Sachs
38
Goldman Sachs
New York
$1.14M -$490K -31,609 -30%
E
39
Ergoteles
New York
$1.13M +$1.15M +74,000 New
OQS
40
Occudo Quantitative Strategies
Florida
$883K +$895K +57,777 New
Two Sigma Investments
41
Two Sigma Investments
New York
$868K +$452K +29,187 +106%
PCM
42
Pinz Capital Management
New York
$792K +$802K +51,800 New
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$776K +$213K +13,783 +37%
Marshall Wace
44
Marshall Wace
United Kingdom
$772K +$782K +50,499 New
Swiss National Bank
45
Swiss National Bank
Switzerland
$694K +$85.2K +5,500 +14%
Alyeska Investment Group
46
Alyeska Investment Group
Illinois
$688K – – –
Ameriprise
47
Ameriprise
Minnesota
$637K +$162K +10,462 +33%
Squarepoint
48
Squarepoint
New York
$618K +$171K +11,035 +38%
AllianceBernstein
49
AllianceBernstein
Tennessee
$614K +$94.5K +6,100 +18%
JF
50
Jump Financial
Illinois
$576K +$584K +37,700 New
1
2
3 4 5

VERV Hedge Fund Activity: Q2 2022 in Review

101 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q2 2022, worth a combined $696M — down 35% from $1.06B a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new VERV positions and 17 closed out — a net gain of 10 holders — while 32 added to existing stakes and 21 trimmed.

The largest buyer was PFM Health Sciences, adding an estimated $7.36M. The largest seller was State Street, cutting an estimated $31.9M.

  • 101 institutional investors held Verve Therapeutics (VERV) as of Q2 2022, up from 92 in Q1 2022.
  • Funds reported $696M of Verve Therapeutics stock for Q2 2022, down 35% quarter-over-quarter.
  • 27 funds opened new Verve Therapeutics positions in Q2 2022 and 17 closed out, a net change of +10 holders.
  • The largest Verve Therapeutics buyer in Q2 2022 was PFM Health Sciences, an estimated $7.36M added.
  • The largest Verve Therapeutics seller in Q2 2022 was State Street, an estimated $31.9M sold.

Based on aggregated 13F filings for Q2 2022.